Table 4 Relative dose intensity of DOC and RAM in patients with or without baseline anemia and prophylactic G-CSF administration.

From: Detection of factors related to treatment reduction in docetaxel and ramucirumab for non-small cell lung cancer treatment

 

Treatment reduction (n, %)

P-value

DOC RDI (%)

P-value

RAM RDI (%)

P-value

Baseline anemia

 Present (n = 100)

16 (16.0%)

 < 0.01**

97.8 ± 6.3

 < 0.01**

93.3 ± 24.0

0.18

 Absent (n = 55)

24 (43.6%)

91.8 ± 10.2

89.5 ± 26.3

Prophylactic G-CSF administration

 Present (n = 106)

16 (15.1%)

 < 0.01**

97.7 ± 6.4

 < 0.01**

95.8 ± 19.3

 < 0.01**

 Absent (n = 49)

24 (49.0%)

91.2 ± 10.3

83.4 ± 32.5

  1. DOC, docetaxel; RDI, relative dose intensity; RAM, ramucirumab; G-CSF, granulocyte colony-stimulating factor.
  2. **P < 0.01.
Back to article page